News | May 26, 2025
Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Global Health has posted net profit of Rs. 481.43 crores for the Financial Year ended March 31, 2025
Indraprastha Medical Corporation has reported total income of Rs. 340.10 crores during the period ended March 31, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
